Scholarlink

<p>Nanoparticle (NP)-mediated delivery of oncolytic viral genomes (vGenomes) represents an innovative strategy to overcome the limitations of conventional oncolytic virotherapy. While traditional live virus delivery systems face substantial challenges including immune-mediated clearance and complex manufacturing workflows, our analysis reveals that encapsulating viral genomes (vGenomes) within surface-functionalized nanoparticles establishes a robust delivery platform. By encapsulating vGenomes within functionalized NPs, this platform achieves tumor-targeted delivery via enhanced permeability and retention (EPR) effects or ligand-mediated active targeting. Intracellular release of vGenomes enables in situ production of viral progeny, inducing immunogenic cell death while evading pre-existing antiviral immunity. Preclinical studies demonstrate that NP-vGenome complexes achieve &gt; 80% tumor regression in murine models and maintain efficacy even in neutralizing antibody-rich environments. This review synthesizes the mechanistic synergy between nanotechnology and oncolytic virotherapy, providing a roadmap for next-generation cancer immunotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nanoparticle-mediated delivery of oncolytic viral genomes: an innovative strategy for tumor-targeted immunotherapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月15日

查看全文
  • Junhan Yang,
  • Binlei Liu

摘要

Nanoparticle (NP)-mediated delivery of oncolytic viral genomes (vGenomes) represents an innovative strategy to overcome the limitations of conventional oncolytic virotherapy. While traditional live virus delivery systems face substantial challenges including immune-mediated clearance and complex manufacturing workflows, our analysis reveals that encapsulating viral genomes (vGenomes) within surface-functionalized nanoparticles establishes a robust delivery platform. By encapsulating vGenomes within functionalized NPs, this platform achieves tumor-targeted delivery via enhanced permeability and retention (EPR) effects or ligand-mediated active targeting. Intracellular release of vGenomes enables in situ production of viral progeny, inducing immunogenic cell death while evading pre-existing antiviral immunity. Preclinical studies demonstrate that NP-vGenome complexes achieve > 80% tumor regression in murine models and maintain efficacy even in neutralizing antibody-rich environments. This review synthesizes the mechanistic synergy between nanotechnology and oncolytic virotherapy, providing a roadmap for next-generation cancer immunotherapy.